Mar 09, 2023 09:07 JST

Source: Eisai

Eisai Certified as a 2023 Health and Productivity Management Outstanding

TOKYO, Mar 09, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been certified as a Health and Productivity Management Outstanding Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry and the Nippon Kenko Kaigi.

Under the Certified Health and Productivity Management Outstanding Organization Recognition Program, the Nippon Kenko Kaigi examines large enterprises, small and medium enterprises and other organizations engaging in initiatives for overcoming health-related challenges in regional communities or for promoting health-conscious activities led by the Nippon Kenko Kaigi. It recognizes outstanding enterprises engaging in efforts for health and productivity management by evaluating from a business-management perspective based on the following criteria: "management philosophy and policies", "organized frameworks", "systems and implementation of measures", and "evaluation and improvement". Eisai exceeded the average of its industry peers in all criteria, receiving particularly high scores for items such as "well adopted by employees" (in the criteria of organized frameworks), "lifestyle improvement" and "other measures*" (in the criteria of systems and implementation of measures). The program was launched in 2017, and this is the fifth time that Eisai was certified as a "White 500" company.

Eisai's corporate concept is to give first thought to patients and the people in the daily living domain, and increase the benefits that health care provides to them as well as meet their diversified healthcare needs worldwide. Eisai calls this the "human health care (hhc)" concept. Eisai regards its employees as an important stakeholder and asset for the realization of its hhc concept. Eisai believes that its commitment to maintaining and improving the health of human resources is fundamental to develop highly engaged employees who are motivated to contribute voluntarily toward the realization of the hhc concept. Eisai issued the "Eisai Health Declaration" in 2019, and has strategically implemented health management for employees from a management perspective.

Eisai will continue to promote health and productivity management to increase non-financial value and further contribute to increasing the benefits of patients and the people in the daily living domain.

*Measures to address health issues specific to women and the elderly, long working hours, mental health, dependents of the company's employees, and prevention of infectious disease during COVID-19 pandemic.

 


Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan
September 25 2023 14:17 JST
 
Eisai: Release of Dementia Disease Awareness Videos for World Alzheimer's Day, September 21
September 21 2023 11:26 JST
 
Eisai Establishes Theoria Technologies Co., Ltd., A New Digital Business Company To Build A Dementia Ecosystem
September 12 2023 18:05 JST
 
Eisai Listed for 22nd Consectutive Year In FTSE4Good Index Series, An Index for Socially Responsible Investment
August 04 2023 12:04 JST
 
Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023
July 20 2023 10:23 JST
 
Eisai to Present the Latest Alzheimer's Disease Pipeline and Research
July 12 2023 09:05 JST
 
Eisai: FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
July 07 2023 12:21 JST
 
New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced
June 30 2023 10:08 JST
 
Eisai's "Nouknow" Will Continue to be Utilized for Brain Health Assessment as Part of The FY2023 Dementia Examination Project by Tokyo Bunkyo City
June 22 2023 16:08 JST
 
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
June 12 2023 09:13 JST
 
More Press release >>

Latest Press Release


More Latest Release >>